Shuttle Pharmaceuticals Holdings is a clinical stage pharmaceutical company utilizing its proprietary technology to develop therapies designed to cure cancers. Co. is developing a pipeline of products designed to address limitations of the existing cancer therapies as well as to extend to the new applications of radiation therapy (RT). Co.'s product candidates include Ropidoxuridine (IPdR), Extended Bio-availability IPdR, and a platform of histone deacetylase inhibitors (SP-1-161, SP-2-225 and SP-1-303). IPdR is Co.'s primary candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. The SHPH average annual return since 2022 is shown above.
The Average Annual Return on the SHPH average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SHPH average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SHPH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|